[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371507-105":59,"doc-detail-371507-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-factors-influencing-retreatment-with-anti-pd-l1-therapies-after-treatment-in-early-stage-cancers-a-modified-delphi-consensus-study","Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers - a modified Delphi consensus study","","Anti-programmed death (ligand) 1 (anti-PD-(L)1) therapies were introduced for metastatic disease and later expanded into adjuvant, perioperative, and neoadjuvant use for early-stage cancers. Evidence for retreatment after relapse following prior neoadjuvant and/or adjuvant anti-PD-(L)1 treatment remains limited and inconclusive, with no clinician guidance on retreatment timing and criteria. This modified Delphi study sought consensus to guide decision-making.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-factors-influencing-retreatment-with-anti-pd-l1-therapies-after-treatment-in-early-stage-cancers-a-modified-delphi-consensus-study/371507/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-factors-influencing-retreatment-with-anti-pd-l1-therapies-after-treatment-in-early-stage-cancers-a-modified-delphi-consensus-study/371507.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of this modified Delphi consensus study?","Question",{"text":112,"@type":113},"To reach consensus on clinical factors that guide decision-making for retreatment with anti-PD-(L)1 therapies after a patient previously received an anti-PD-(L)1 agent in early-stage cancer treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study conduct the Delphi process?",{"text":117,"@type":113},"It combined a clinician survey across 10 countries with three real-time virtual Delphi panels involving clinical experts who completed the survey.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were agreed upon as important for retreatment decisions?",{"text":121,"@type":113},"Panelists agreed decisions should consider prior immune-related adverse events/toxicity, time-related factors (such as time since completing treatment or discontinuation), and previous patient response; they also highlighted country-specific practices, treatment availability, and reimbursement.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371507,1790554359,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Position article and guidelines  \nClinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study  \nLajos Pusztai,1 Vernon K Sondak,2 Raquel Aguiar-Ibáñez,3 Federico Cappuzzo,4 Christos Chouaid  ,5 Chris Elder,6 Yosuke Hirasawa,7 Masaru Ishida,8 Robert Jones,9 Seung Hyeun Lee,10,11 Ryuichi Mizuno,12 Masayoshi Nagata,13 David Okonji,14 Phillip Parente,15 Bhavesh Shah,16 Alexander Sun,17 Dominihemberg Ferreira,18 Carmel Spiteri,19 Andrea Lauer,20 Amrit Kaliasethi,21 Carol Kao,22 Smita Kothari,23 Jan McKendrick21  \nTo cite: Pusztai L, Sondak VK, Aguiar-Ibáñez R, et al. Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study. Journal for ImmunoTherapy of Cancer 2025;13:e011184 . doi:10 . 1136/ jitc-2024-011184  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-011184](jitc-2024-011184)) .  \nAccepted 09 May 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nRaquel Aguiar-Ibáñez;  \nraquel.aguiar-ibanez@merck. com  \nABSTRACT  \nAnti-programmed death (ligand) 1 (anti-PD-(L)1) therapies were first introduced in the metastatic setting and  \nhave since been approved and reimbursed for treating early-stage cancers in the adjuvant, perioperative, and neoadjuvant settings in many cancer types. Current evidence supporting anti-PD(L)-1 retreatment after relapse with prior neoadjuvant and/or adjuvant anti-PD(L)1 therapy is limited and inconclusive. There is no guidance for clinicians on how and when to retreat with anti-PD-(L)1 therapies when anti-PD-(L)1 therapy was administered in the neoadjuvant and/or adjuvant setting. This study aimed to reach consensus on factors to guide decision-making regarding retreatment with anti-PD-(L)1 therapies after prior therapy with an anti-PD-(L)1 agent. This modified Delphi study consisted of a clinician survey across 10 countries followed by three real-time virtual Delphi panels involving clinical experts who had completed the survey. Clinical experts were experienced in using anti-PD-(L)1 treatments in early-stage cancers and/or as retreatment of patients with recurrences following early-stage treatment with anti-PD-(L)1 therapies. Of 28 clinicians providing survey responses, 20 participated in one of three Delphi panels. There was consensus that retreatment can be defined as ‘repeated treatment with the same therapeutic class following relapse after or during neoadjuvant and/oradjuvant treatment.’ All three panels agreed that decisions around retreatment should consider ‘prior immunerelated adverse events/toxicity,’‘time-related factors’(eg, time since completion of full treatment course and since discontinuation) and ‘previous patient response’(often referred to by clinicians as tumor response, which may have reflected their experience with metastatic disease) . Other factors identified as important included country-specific practices, treatment availability, and reimbursement. Generally, the clinical experts considered that retreatment could be considered from ≥3 to 6 months after stopping initial anti-PD-(L)1 treatment, or from ≥6 months after relapse/recurrence. In conclusion, clinicians across different regions recognized a role for retreating patients with anti-PD-(L)1 therapies after initial anti-PD-  \n(L)1 treatment for early-stage cancers. Consensus was reached on some factors to consider regarding whether and when to retreat, although differences in clinical practice between countries/geographical regions made it difficult to achieve consensus for some more nuanced elements of retreatment. Further evidence ","cbCaideEFmmUoBhH","https://ap.wps.com/l/cbCaideEFmmUoBhH","pdf",1161636,13,"English","# Abstract\n# Background","[{\"question\":\"What was the goal of this modified Delphi consensus study?\",\"answer\":\"To reach consensus on clinical factors that guide decision-making for retreatment with anti-PD-(L)1 therapies after a patient previously received an anti-PD-(L)1 agent in early-stage cancer treatment.\"},{\"question\":\"How did the study conduct the Delphi process?\",\"answer\":\"It combined a clinician survey across 10 countries with three real-time virtual Delphi panels involving clinical experts who completed the survey.\"},{\"question\":\"Which factors were agreed upon as important for retreatment decisions?\",\"answer\":\"Panelists agreed decisions should consider prior immune-related adverse events/toxicity, time-related factors (such as time since completing treatment or discontinuation), and previous patient response; they also highlighted country-specific practices, treatment availability, and reimbursement.\"}]","Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers - a modified Delphi consensus study | PDF",1790192231,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/560384873869345e825e6e5ff9d47edc.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b72e7a075d76f66c2c2ca2828cf9e85d.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/855dd5316e0e306da18a5232594b3ddc.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cd5a5109bbcf0d19b053c5fb57f6342.webp",980,1306]